New Evidence in First-Line AML & Exploring Outcomes with Fixed-Duration Treatment in CLL

Thursday, November 12, 2020, 9:00 PM ET

Harry Erba, MD, PhD Professor, Department of Medicine, Director of the Leukemia Program and Director of Phase I Development in Hematologic Malignancies, Duke University, Durham, NC

Nakhle Saba, MD Associate Professor of Medicine, Section of Hematology and Medical Oncology Tulane University, New Orleans, LA

REGISTER via link below

https:// abbvie.meintl.com/00071-OB21-20

DURING THIS INTERACTIVE PROGRAM WE WILL:

• Recognize VENCLEXTA as a BCL-2 inhibitor for 1L AML, and 1L and R/R CLL • Review the phase 3 efficacy and safety outcomes of VENCLEXTA + azacitidine from the pivotal VIALE-A study

for patients with 1L AML, ineligible for intensive induction chemotherapy due to age or comorbidities • Explore the efficacy and safety outcomes of VENCLEXTA’s chemo-free, fixed duration CLL regimens